CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?


CRISPR Therapeutics Ownership Summary


CRISPR Therapeutics is owned by 76.47% institutional investors, 1.79% insiders, and 21.73% retail investors. Ark investment management is the largest institutional shareholder, holding 10.53% of CRSP shares. ARK Innovation ETF is the top mutual fund, with 7.94% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics76.47%1.79%21.73%
SectorHealthcare Stocks 57.00%9.26%33.74%
IndustryBiotech Stocks 68.69%8.88%22.43%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management8.97M10.53%$353.18M
Capital investors8.74M10.26%$344.15M
T. rowe price investment management3.81M4.47%$150.03M
Blackrock2.78M3.40%$150.03M
Blackrock funding, inc. /de2.76M3.24%$108.61M
Sumitomo mitsui trust2.75M3.22%$108.07M
Nikko asset management americas2.75M3.22%$108.07M
State street2.49M2.95%$98.07M
Fmr2.22M2.61%$87.51M
Ubs group1.98M2.33%$78.09M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management498.56K22.62%$19.62M
Sr one capital management, lp1.05M10.07%$41.29M
Spear rsc165.00K6.29%$8.91M
Nea management company1.59M3.53%$62.50M
Ark investment management8.97M2.94%$353.18M
Contrarius investment management685.72K2.32%$37.04M
Ecor1 capital1.39M2.07%$54.68M
Eagle health investments lp197.00K1.87%$10.64M
Nikko asset management americas2.75M1.17%$108.07M
Green alpha advisors24.63K0.78%$969.40K

Top Buyers

HolderShares% AssetsChange
Orbis allan gray1.48M0.31%1.48M
Ark investment management8.97M2.94%1.47M
Ubs group1.98M0.01%1.31M
T. rowe price investment management3.81M0.09%1.07M
Capital investors8.74M0.06%816.79K

Top Sellers

HolderShares% AssetsChange
Bellevue group---610.00K
Farallon capital management---530.00K
State street2.49M0.00%-501.46K
Morgan stanley597.68K0.00%-488.25K
Federated hermes---447.61K

New Positions

HolderShares% AssetsChangeValue
Orbis allan gray1.48M0.31%1.48M$58.10M
Norges bank443.54K0.00%443.54K$17.46M
Susquehanna fundamental investments92.39K0.05%92.39K$3.64M
Imc-chicago86.47K0.00%86.47K$3.40M
Raymond james financial82.09K0.00%82.09K$3.23M

Sold Out

HolderChange
Impact partnership wealth-1.00
Toronto dominion bank-4.00
Baldwin brothers llc/ma-4.00
Financial gravity asset management-5.00
Abich financial wealth management-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024420-5.83%64,513,2688.48%761.57%174-118-10.61%
Sep 30, 2024437-9.15%59,424,788-0.24%691.31%167-19.71%1311.55%
Jun 30, 2024478-7.54%59,547,6001.78%721.42%205-12.02%129-9.15%
Mar 31, 20245170.58%58,507,2425.59%711.48%233-10.73%14215.45%
Dec 31, 202351417.62%55,408,0780.82%691.45%26131.16%12314.95%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Innovation ETF6.81M7.94%236.55K
ARK Disruptive Innovation Full Composite6.44M7.54%1.25M
American Funds New Perspective A4.79M5.61%100.58K
Capital Group New Perspective Comp4.79M5.61%100.58K
ARK Genomic Revolution ETF1.85M2.15%4.57K
ARK Genomic Revolution1.79M2.10%33.41K
SPDR® S&P Biotech ETF1.79M2.10%-17.39K
American Funds SMALLCAP World A1.62M1.90%489.84K
T. Rowe Price US Mid-Cap Growth Equity1.50M1.75%501.10K
T. Rowe Price Mid-Cap Growth1.50M1.75%-

Recent Insider Transactions


DateNameRoleActivityValue
Feb 19, 2025Kulkarni Samarth Chief Executive OfficerSell$365.80K
Feb 19, 2025Bruno Julianne Chief Operating OfficerSell$17.58K
Feb 18, 2025Kulkarni Samarth Chief Executive OfficerSell$640.78K
Feb 19, 2025KASINGER JAMES R. General Counsel and SecretarySell$102.80K
Feb 18, 2025KASINGER JAMES R. General Counsel and SecretarySell$516.69K

Insider Transactions Trends


DateBuySell
2025 Q1-5
2024 Q4-5
2024 Q3--
2024 Q2-3
2024 Q1-15

CRSP Ownership FAQ


Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 76.47%, followed by 1.79% insiders and 21.74% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 68.69%, which CRISPR Therapeutics exceeds.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (8.97M shares, 10.53%), Capital investors (8.74M shares, 10.26%), and T. rowe price investment management (3.81M shares, 4.47%). Together, they hold 25.26% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 22.62% of its assets in 498.56K CRISPR Therapeutics shares, valued at 19.62M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Innovation ETF is the top mutual fund holder of CRISPR Therapeutics shares, with 7.94% of its total shares outstanding invested in 6.81M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools